Opportunities in viral vector manufacturing arise from rising demand for GMP-grade materials and increasing gene therapy ...
After the FDA revoked Sarepta Therapeutics’ platform designation in July, Krystal Biotech is “poised to be the first major ...
Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the best mid cap growth stocks to invest in now. Earlier on June 4, Sarepta Therapeutics announced that the US FDA has granted Platform Technology ...
Dublin, Oct. 09, 2025 (GLOBE NEWSWIRE) -- The "Viral Vector Manufacturing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By ...
Receiving a platform technology designation from the FDA is a tremendous milestone for our development team and Krystal, both as recognition of the reproducibility and scalability of our HSV-1 gene ...
Thermo Fisher will equip Dr. Park CDMO’s new facility with advanced bioreactors to scale viral vector manufacturing.
NIVELLES, Belgium--(BUSINESS WIRE)--Univercells Technologies, a Donaldson Life Sciences business and global provider of bioprocessing solutions, announced the launch of the scale-X™ nitro controller, ...
MARTINSRIED, Germany--(BUSINESS WIRE)--SIRION Biotech GmbH announced today that Beam Therapeutics licensed rights to use SIRION Biotech’s LentiBOOST™ for use in their CAR-T cell products. CAR-T cell ...
Hosted on MSN
Gene Delivery Systems: Viral vs. Non-Viral Vectors
Gene therapy involves the introduction of foreign genomic materials into host cells to trigger clinical benefits. 1 Over the years, scientists have developed numerous viral and non-viral vectors to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback